Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 15 17
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Carcinoma, Verrucous 44
Carcinoma Verrucous 55
Warty Carcinoma 12


External Ids:

Disease Ontology 12 DOID:3737
MeSH 44 D018289
NCIt 50 C3781
SNOMED-CT 68 89906000
UMLS 72 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to squamous cell papilloma and oral cancer. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Cevimeline and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include cervix, skin and bone, and related phenotypes are Decreased viability with paclitaxel and digestive/alimentary

Wikipedia : 75 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.6 TP53 CDKN2A
2 oral cancer 30.9 TP53 CDKN2A CCND1
3 papilloma 30.9 TP53 KRT10 CDKN2A CCND1
4 keratinizing squamous cell carcinoma 30.9 TP53 CDKN2A
5 cheilitis 30.9 TP53 MDM2
6 anal squamous cell carcinoma 30.9 TP53 CDKN2A
7 anogenital venereal wart 30.8 TP53 CDKN2A
8 suppressor of tumorigenicity 3 30.8 TP53 CDKN2A
9 basaloid squamous cell carcinoma 30.7 TP53 CDKN2A
10 vulvar intraepithelial neoplasia 30.7 TP53 KRT10
11 actinic cheilitis 30.7 TP53 MDM2
12 scrotal carcinoma 30.7 TP53 CDKN2A
13 vulva squamous cell carcinoma 30.7 TP53 CDKN2A
14 megaesophagus 30.6 TP53 CDKN2A
15 oral leukoplakia 30.6 TP53 CDKN2A CCND1
16 endometrial squamous cell carcinoma 30.6 CDKN2A CCND1
17 inverted papilloma 30.4 TP53 CDKN2A CCND1
18 penile cancer 30.4 TP53 CDKN2A CCND1
19 vulva cancer 30.4 TP53 CDKN2A
20 oropharynx cancer 30.2 TP53 CDKN2A CCND1
21 esophageal disease 30.2 TP53 CDKN2A CCND1
22 laryngeal squamous cell carcinoma 30.2 TP53 CDKN2A CCND1
23 larynx cancer 30.2 TP53 CDKN2A CCND1
24 barrett esophagus 30.2 TP53 CDKN2A CCND1
25 esophageal cancer 30.0 TP53 MDM2 CDKN2A CCND1
26 retinoblastoma 30.0 TP53 MDM2 CDKN2A CCND1
27 bladder cancer 29.6 TP53 MDM2 CDKN2A CCND1
28 keratoacanthoma 29.6 TP53 KRT10
29 endometrial cancer 29.6 TP53 MDM2 CDKN2A CCND1
30 squamous cell carcinoma, head and neck 29.3 TP53 CDKN2A CCND1
31 cervical cancer 29.2 TP53 SLC2A1 MDM2 CDKN2A CCND1
32 larynx verrucous carcinoma 12.5
33 esophagus verrucous carcinoma 12.5
34 supraglottis verrucous carcinoma 12.5
35 cervical verrucous carcinoma 12.5
36 vulva verrucous carcinoma 12.4
37 penis verrucous carcinoma 12.4
38 glottis verrucous carcinoma 12.4
39 subglottis verrucous carcinoma 12.4
40 urethral verrucous carcinoma 12.3
41 penis non-invasive verrucous carcinoma 12.3
42 buschke lowenstein tumor 11.7
43 proliferative verrucous leukoplakia 11.6
44 anal buschke-lowenstein tumor 11.6
45 bladder verrucous squamous cell carcinoma 11.3
46 squamous cell carcinoma 10.6
47 bladder squamous cell carcinoma 10.6 TP53 CDKN2A
48 zika virus infection 10.6 TP53 MDM2
49 ring chromosome 7 10.6 TP53 MDM2
50 spitz nevus 10.6 TP53 CDKN2A

Graphical network of the top 20 diseases related to Verrucous Carcinoma:

Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

GenomeRNAi Phenotypes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00293-A 8.8 KRT10 SLC2A1 TP53

MGI Mouse Phenotypes related to Verrucous Carcinoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.72 CCND1 CDKN2A LRIG1 MDM2 TP53
2 nervous system MP:0003631 9.7 CCND1 CDKN2A LRIG1 MDM2 NOTCH4 SLC2A1
3 neoplasm MP:0002006 9.65 CCND1 CDKN2A LRIG1 MDM2 TP53
4 no phenotypic analysis MP:0003012 9.35 CDKN2A LRIG1 MDM2 SLC2A1 TP53
5 normal MP:0002873 9.1 CCND1 LRIG1 MDM2 MSN NOTCH4 TP53

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
Promethazine Approved, Investigational Phase 3 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
Histamine Approved, Investigational Phase 3 51-45-6 774
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
16 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
17 Dermatologic Agents Phase 3
18 Antineoplastic Agents, Phytogenic Phase 3
19 Antidotes Phase 3
20 Cola Phase 3
21 Liver Extracts Phase 3
22 Neurotransmitter Agents Phase 3
23 Cholinergic Agents Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Muscarinic Agonists Phase 3
26 Autonomic Agents Phase 3
27 14-alpha Demethylase Inhibitors Phase 2, Phase 3
28 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
30 Steroid Synthesis Inhibitors Phase 2, Phase 3
31 Hormone Antagonists Phase 2, Phase 3
32 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
34 Contraceptives, Oral Phase 3
35 Contraceptive Agents Phase 3
36 Central Nervous System Stimulants Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Appetite Stimulants Phase 3
Megestrol Phase 3 3562-63-8 3080587 19090
40 Calcium, Dietary Phase 3
41 Antidepressive Agents Phase 3
42 Hypnotics and Sedatives Phase 3
43 Histamine Antagonists Phase 3
44 Central Nervous System Depressants Phase 3
Histamine Phosphate Phase 3 51-74-1 65513
46 Psychotropic Drugs Phase 3
47 Antidepressive Agents, Tricyclic Phase 3
48 Analgesics Phase 3
49 Anesthetics, Intravenous Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
2 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
3 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
6 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
7 Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
8 A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00820248 Phase 3 cisplatin
9 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
14 A Phase III, Randomized, Double-Blind Study of Lactobacillus Brevis CD2 Lozenges Versus Placebo in the Prevention of Acute Oral Mucositis (OM) in Patients With Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
17 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
18 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
20 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
21 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
22 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
23 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
24 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
25 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
26 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
27 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
28 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
29 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
30 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
31 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
32 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
33 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
34 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
35 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
36 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
37 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
38 Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck Completed NCT00738868 Phase 2
39 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
40 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
41 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
42 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
43 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
44 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
45 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
46 A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
47 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
48 Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
49 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
50 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

Cervix, Skin, Bone, Brain, Lung, Lymph Node, Liver

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 1190)
# Title Authors PMID Year
Shifts in cellular localization of moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. 9 38
12787041 2003
Expression of moesin and its associated molecule CD44 in epithelial skin tumors. 9 38
9696288 1998
Is primary radiotherapy an acceptable treatment modality for verrucous carcinoma of the larynx? 38
30950508 2019
A Case of Oral Florid Papillomatosis (Verrucous Carcinoma) With Lack of Evidence for Human Papillomavirus Involvement. 38
31335422 2019
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. 38
30841011 2019
A Novel Surface Enhanced Raman Catheter for Rapid Detection, Classification, and Grading of Oral Cancer. 38
31081261 2019
Verruciform and Condyloma-like Squamous Proliferations in the Anogenital Region. 38
30203987 2019
A first case of primary gastric verrucous carcinoma with isolated squamous epithelium in the stomach. 38
30761414 2019
Experience with endoscopic resection of oesophageal verrucous carcinoma and literature review. 38
31229974 2019
Verrucous Carcinoma Arising in Association With Giant Condyloma. 38
30185090 2019
Diagnostic utility of microsurgical carbon dioxide laser excision of oral potentially malignant lesions vs incisional biopsy: a retrospective histopathological review. 38
30948343 2019
Verrucous carcinoma of the upper lip: An exuberant presentation in a patient with other synchronous lesions. 38
31274469 2019
Verrucous Carcinoma of the Vulva: A Case Report and Literature Review. 38
31002657 2019
Inter-observer Variability in the Diagnosis of Proliferative Verrucous Leukoplakia: Clinical Implications for Oral and Maxillofacial Surgeon Understanding: A Collaborative Pilot Study. 38
30972634 2019
Verrucous carcinoma arising in a long standing Buschke-Löwenstein tumor. 38
30997098 2019
HPV-Related Papillary Lesions of the Oral Mucosa: A Review. 38
30693456 2019
Human papillomavirus infection is not involved in esophageal verrucous carcinoma. 38
30423307 2019
Expanded Expression of Toll-Like Receptor 2 in Proliferative Verrucous Leukoplakia. 38
30888638 2019
Verrucous carcinoma: An unexpected finding arising from a burn scar. 38
30809566 2019
Risk Assessment of Smokeless Tobacco among Oral Precancer and Cancer Patients in Eastern Developmental Region of Nepal 38
30803200 2019
[Experience of diagnosis and treatment for 89 patients with Marjolin's ulcers in lower limbs]. 38
30837387 2019
Downregulation of Notch4 - a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma. 38
29162408 2019
Anogenital Verrucous Carcinoma-A case report. 38
30508696 2019
Lichenoid Characteristics in Premalignant Verrucous Lesions and Verrucous Carcinoma of the Oral Cavity. 38
30671763 2019
Non-urothelial carcinomas of the bladder. 38
30565306 2019
Organ-Sparing Surgery for a Giant Verrucous Carcinoma of the Penile Shaft: A Case Report and Review of the Literature. 38
30918740 2019
Treatment of verrucous carcinoma in penis with topical aminolevulinic acid photodynamic therapy: An effective and safe treatment method. 38
30205190 2018
Verrucous carcinoma arising from a previous cystic lesion: a case report. 38
30397593 2018
Recurrent oral squamous papilloma in a pediatric patient: Case report and review of the literature. 38
30560835 2018
Oral carcinoma cuniculatum, an unacquainted variant of oral squamous cell carcinoma: A systematic review. 38
30607347 2018
Verrucous carcinoma of the oesophagus. 38
28116819 2018
A Rare Variant of Penile Squamous Cell Carcinoma in a Man with Paraplegia. 38
30416897 2018
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. 38
30111295 2018
Verrucous carcinoma of the esophagus: A rare entity with a difficult diagnosis. 38
29452967 2018
Syringocystadenoma Papilliferum in Coexistence With Verrucous Carcinoma on the Face. 38
29112527 2018
Recalcitrant lip verrucous carcinoma successfully treated with acitretin after carbon dioxide laser ablation. 38
29998178 2018
Single-stage reconstruction of large defect of oral commissure and lips by submental artery island flap. 38
30546239 2018
Carcinoma cuniculatum in the tongue of a patient with oral lichen planus: Unusual presentation. 38
30127207 2018
Systemic therapy in non-conventional cancers of the larynx. 38
29909903 2018
MCM-2 expression differentiates potentially malignant verrucous lesions from oral carcinomas. 38
29661732 2018
Verrucous carcinoma of the esophagus-remains a diagnostic enigma. 38
29748561 2018
A rare anatomical location of human papillomavirus-related penile warty carcinoma: Simultaneous axillary involvement. 38
29536967 2018
A Case of Oral Florid Papillomatosis (Verrucous Carcinoma) With Lack of Evidence for Human Papillomavirus Involvement. 38
29697424 2018
The Spectrum of Oral Lesions Presenting Clinically With Papillary-Verrucous Features. 38
28923272 2018
BCL-X expression in oral cancer: Comparison between oral squamous cell carcinoma and verrucous carcinoma. 38
29652014 2018
Epidemiology and survival outcomes of sinonasal verrucous carcinoma in the United States. 38
28865078 2018
Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. 38
29235153 2018
A population-based analysis of verrucous carcinoma of the oral cavity. 38
28850720 2018
Corrigendum to "Mistaken Diabetic Ulcers: A Case of Bilateral Foot Verrucous Carcinoma". 38
29849220 2018
Two Cases of Verrucous Carcinoma: Revisiting the Definition. 38
29540646 2018

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.82 TP53 NOTCH4 MDM2 CCND1
Show member pathways
12.71 TP53 MDM2 CDKN2A CCND1
Show member pathways
Show member pathways
Show member pathways
12.47 TP53 SLC2A1 MDM2 CCND1
Show member pathways
12.45 TP53 MDM2 CDKN2A CCND1
8 12.39 TP53 MDM2 CDKN2A CCND1
Show member pathways
12.25 TP53 MDM2 CDKN2A CCND1
Show member pathways
12.24 TP53 MDM2 CCND1
11 12.24 TP53 MDM2 CDKN2A CCND1
12 12.23 TP53 SLC2A1 CDKN2A CCND1
Show member pathways
12.2 TP53 CDKN2A CCND1
14 12.15 TP53 MDM2 CDKN2A CCND1
15 12.15 TP53 MSN MDM2 CCND1
Show member pathways
12.1 TP53 MDM2 CCND1
17 12.01 TP53 MDM2 CCND1
18 12 TP53 MDM2 CCND1
19 12 TP53 MDM2 CDKN2A CCND1
20 11.92 TP53 NOTCH4 MIR125A MDM2 CDKN2A CCND1
21 11.91 TP53 MDM2 CDKN2A
Show member pathways
11.91 TP53 NOTCH4 CCND1
23 11.83 TP53 MDM2 CDKN2A
24 11.82 TP53 MDM2 CDKN2A CCND1
25 11.74 TP53 MDM2 CCND1
26 11.71 TP53 MDM2 CDKN2A CCND1
Show member pathways
11.64 TP53 MDM2 CDKN2A
28 11.64 TP53 MDM2 CDKN2A
29 11.57 TP53 MDM2 CDKN2A
30 11.48 TP53 MDM2 CCND1
31 11.44 TP53 CDKN2A CCND1
32 11.42 TP53 MDM2 CDKN2A CCND1
33 11.34 TP53 MDM2 CCND1
34 11.25 TP53 SLC2A1
35 11.19 TP53 SLC2A1 MDM2 CDKN2A
36 11.18 TP53 CCND1
37 11.16 TP53 MDM2
38 11.16 TP53 MDM2 CDKN2A
39 11.1 TP53 SLC2A1 NOTCH4 MDM2 CCND1
Show member pathways
10.95 TP53 MDM2 CDKN2A
41 10.92 TP53 MDM2 CDKN2A

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.23 TP53 SLC2A1 NOTCH4 MSN MDM2 KRT10

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein-containing complex assembly GO:0065003 9.58 TP53 SLC2A1 MDM2
2 protein sumoylation GO:0016925 9.54 MDM2 CDKN2A
3 response to steroid hormone GO:0048545 9.52 MDM2 CCND1
4 response to antibiotic GO:0046677 9.51 TP53 MDM2
5 cellular response to gamma radiation GO:0071480 9.49 TP53 MDM2
6 negative regulation of cell cycle arrest GO:0071157 9.48 MDM2 CCND1
7 positive regulation of protein export from nucleus GO:0046827 9.46 TP53 MDM2
8 response to iron ion GO:0010039 9.43 MDM2 CCND1
9 response to magnesium ion GO:0032026 9.37 MDM2 CCND1
10 replicative senescence GO:0090399 9.32 TP53 CDKN2A
11 amyloid fibril formation GO:1990000 9.26 MDM2 CDKN2A
12 mitotic G1 DNA damage checkpoint GO:0031571 9.16 TP53 CCND1
13 positive regulation of gene expression GO:0010628 9.02 TP53 MSN MIR125A MDM2 CDKN2A
14 cellular response to actinomycin D GO:0072717 8.96 TP53 MDM2

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.46 TP53 MSN CDKN2A CCND1
2 SUMO transferase activity GO:0019789 9.26 MDM2 CDKN2A
3 enzyme binding GO:0019899 9.26 TP53 MSN MDM2 CCND1
4 disordered domain specific binding GO:0097718 8.8 TP53 MDM2 CDKN2A

Sources for Verrucous Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....